Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Moderna : Canada review of Pfizer's coronavirus vaccine candidate should be done soon -minister

12/02/2020 | 02:30pm EST

OTTAWA, Dec 2 (Reuters) - Canadian health authorities should soon complete their regulatory review of Pfizer Inc's coronavirus vaccine candidate, Health Minister Patty Hajdu said on Wednesday.

Hajdu posted her comment on Twitter shortly after Britain approved the candidate. Pfizer developed the vaccine with its German partner BioNTech SE.

Health Canada is reviewing vaccine candidates from Pfizer, AstraZeneca Plc, Modern Inc and Johnson & Johnson but has yet to approve any of them.

"The news that the Pfizer/BioNTech vaccine has been approved in the U.K. is encouraging. Health Canada’s review of this candidate is ongoing, and is expected to be completed soon," Hajdu tweeted.

Canada's Liberal government, which has signed deals with a total of seven vaccine manufacturers, says doses could arrive soon after any approval.

A second wave of the virus is sweeping Canada, setting daily records for the number of new daily cases. So far Canada has reported a total of 383,468 cases of COVID-19 and 12,212 deaths.

Alberta Premier Jason Kenney said Ottawa has assured his provincial government that shipments will start arriving by Jan. 4. Kenney announced the formation of a task force to distribute vaccine shipments and said his government was aiming to immunize 435,000 people, or 10% of Alberta's population, in the first three months next year.

Alberta has the second-highest rate of total cases among provinces. On Wednesday it reported another 1,685 new cases and 10 deaths.

The Canadian Broadcasting Corp reported that Alberta had asked the federal government and Canadian Red Cross to supply field hospitals, as its health-care system becomes overwhelmed. Kenney said the inquiry was simply responsible planning and that Alberta was not close to needing such capacity. (Reporting by David Ljunggren in Ottawa; additional reporting by Rod Nickel in Winnipeg; Editing by Grant McCool and Stephen Coates)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.92% 7662 Delayed Quote.3.66%
MODERNA, INC. -0.05% 129.65 Delayed Quote.24.10%
All news about MODERNA, INC.
12:27pDoes Getting the Covid-19 Vaccine Stop You Spreading It? Scientists Don't Kno..
DJ
06:06aHow Africa Is Leading From Behind in Global Coronavirus Vaccine Race
AQ
04:04aMODERNA : Canadians who have had COVID-19 should still get the vaccine, experts ..
AQ
01/17LONZA : Partner Moderna to Deliver 7.5 Million COVID-19 Shots to Switzerland By ..
MT
01/17MODERNA : Vaccination campaign gets underway in nine Cree communities in norther..
AQ
01/17ONTARIO TO EXPAND BIG-BOX-RETAIL BLI : McNaughton
AQ
01/17Swiss to get Moderna vaccine in tranches until mid-year - Blick
RE
01/16MODERNA : U.S. COVID-19 vaccine supplies strain to meet wider eligibility, secon..
RE
01/15PFIZER : Anger in states over pace of COVID-19 vaccine allotments
AQ
01/15MODERNA : WHO sees poorer countries getting first COVID vaccines this quarter
RE
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 -566 M - -
Net cash 2020 2 865 M - -
P/E ratio 2020 -108x
Yield 2020 -
Capitalization 51 304 M 51 304 M -
EV / Sales 2020 94,7x
EV / Sales 2021 4,51x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 136,60 $
Last Close Price 129,65 $
Spread / Highest target 42,7%
Spread / Average Target 5,36%
Spread / Lowest Target -46,8%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601
HANGZHOU TIGERMED CONSULTING CO.,LTD0.43%21 655